Best Value Stocks To Invest In Right Now

&l;p&g;Life insurance is a fundamental risk management tool for a secure financial lifestyle. Primarily, it functions as an income replacement insurance product during an individual&a;rsquo;s working years. In many cases, life insurance is set up to provide financial security for family members or to pay off liabilities in the event of an untimely and premature death. Because the likelihood of the death of the insured occurring during working years is relatively low, but the impact would be devastating, insurance is a perfect fit for the situation. However, many people not only buy term insurance, but they also buy a permanent life insurance product. Permanent life insurance is different than term insurance as it offers the potential of an investment component or cash value in addition to life insurance coverage. Because these insurance products will last for life, past your working years and through retirement, it is important to think about permanent products as assets that can also help support a secure retirement.

Best Value Stocks To Invest In Right Now: Exelixis, Inc.(EXEL)

Advisors’ Opinion:

  • [By Dan Caplinger]

    Tuesday was an upbeat day on Wall Street — the Dow Jones Industrials climbed more than 100 points, and other major market indexes posted gains of around half a percent. A strong economy and optimism about the upcoming earnings results for the third-quarter have helped boost market confidence over the past month, and even issues like tariff disputes and the midterm elections haven’t been enough to push the key stock indexes far off their record highs. Yet even though investors were in a good mood generally Tuesday, company-specific bad news sent some shares lower. SandRidge Energy (NYSE:SD), Sonos (NASDAQ:SONO), and Exelixis (NASDAQ:EXEL) were among the worst performers on the day. Below, we’ll look more closely at these companies to tell you why their shares did so poorly.

  • [By ]

    Another biotech worth  considering is Exelixis Inc. (NASDAQ: EXEL).

    The company recently received FDA approval of a new cancer treatment that according to a recent NASDAQ industry report “should further boost demand” and send share values higher.

  • [By Paul Ausick]

    Exelixis Inc. (NASDAQ: EXEL) traded down about 4.4% Tuesday to post a new 52-week low of $16.92 after closing Monday at $17.69. The stock’s 52-week high is $32.50. Volume was 25% below the daily average of about 4.2 million shares. The company had no specific news and shares have recovered enough to get on track for a daily gain of around 1%.

  • [By Max Byerly]

    Shares of Exelixis, Inc. (NASDAQ:EXEL) have received a consensus recommendation of “Buy” from the sixteen research firms that are covering the stock, Marketbeat reports. Three investment analysts have rated the stock with a sell recommendation, two have given a hold recommendation, nine have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $30.70.

  • [By Brian Feroldi, Keith Speights, and Sean Williams]

    With that in mind, we asked a team of Motley Fool investors to highlight a biotech stock that they think is a strong buy right now. Here’s why they picked Exelixis (NASDAQ:EXEL), Celgene (NASDAQ:CELG), and Ionis Pharmaceuticals (NASDAQ:IONS). 

  • [By Stephan Byrd]

    Exelixis, Inc. (NASDAQ:EXEL) VP Patrick J. Haley sold 3,663 shares of the business’s stock in a transaction dated Friday, May 18th. The stock was sold at an average price of $21.61, for a total transaction of $79,157.43. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.

Best Value Stocks To Invest In Right Now: Resolute Energy Corporation(REN )

Advisors’ Opinion:

  • [By Ethan Ryder]

    Shares of Resolute Energy Corp (NYSE:REN) have received an average rating of “Hold” from the nine ratings firms that are currently covering the firm, Marketbeat reports. Seven analysts have rated the stock with a hold recommendation and two have assigned a buy recommendation to the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $39.17.

  • [By Max Byerly]

    Republic Protocol (CURRENCY:REN) traded 15% lower against the U.S. dollar during the one day period ending at 16:00 PM E.T. on June 23rd. Over the last week, Republic Protocol has traded down 25.4% against the U.S. dollar. One Republic Protocol token can now be purchased for approximately $0.0590 or 0.00000961 BTC on popular cryptocurrency exchanges including OKEx, IDEX, DDEX and Cobinhood. Republic Protocol has a market capitalization of $32.57 million and $2.71 million worth of Republic Protocol was traded on exchanges in the last 24 hours.

  • [By Shane Hupp]

    Republic Protocol (CURRENCY:REN) traded 8.6% lower against the dollar during the 1-day period ending at 12:00 PM E.T. on June 13th. Republic Protocol has a total market capitalization of $39.37 million and $1.56 million worth of Republic Protocol was traded on exchanges in the last 24 hours. Over the last week, Republic Protocol has traded 22.7% lower against the dollar. One Republic Protocol token can now be purchased for $0.0757 or 0.00001210 BTC on popular exchanges including Cobinhood, IDEX, DDEX and Liqui.

Best Value Stocks To Invest In Right Now: MoSys, Inc.(MOSY)

Advisors’ Opinion:

  • [By Lisa Levin] Gainers
    Pacific Biosciences of California, Inc. (NASDAQ: PACB) rose 11.4 percent to $2.93 in pre-market trading.
    Check-Cap Ltd. (NASDAQ: CHEK) shares rose 6.3 percent to $4.76 in pre-market trading as the company announced the publication of CE Mark multicenter clinical study results on C-Scan® in Gut.
    Acacia Communications, Inc. (NASDAQ: ACIA) rose 6 percent to $ 35.20 in pre-market trading.
    Cellect Biotechnology Ltd. (NASDAQ: APOP) rose 6 percent to $7.60 in pre-market trading.
    Hexindai Inc. (NASDAQ: HX) rose 5.7 percent to $12.70 in pre-market trading.
    MoSys, Inc. (NASDAQ: MOSY) shares rose 5.3 percent to $2.07 in pre-market trading.
    Micron Technology, Inc. (NASDAQ: MU) rose 5 percent to $58.20 in pre-market trading after reporting a $10 billion buyback plan.
    Golden Ocean Group Limited (NASDAQ: GOGL) rose 4.1 percent to $8.63 in pre-market trading.
    MorphoSys AG (NASDAQ: MOR) rose 3.5 percent to $26.99 in pre-market trading.
    Cyren Ltd (NASDAQ: CYRN) shares rose 3.4 percent to $2.90 in pre-market trading. after reporting Q1 results.
    Box, Inc. (NYSE: BOX) rose 3.4 percent to $28.76 in pre-market trading.
    Kohl's Corporation (NYSE: KSS) shares rose 3.3 percent to $67.60 in the pre-market trading session after the company reported upbeat quarterly earnings.
    Micro Focus International plc (NYSE: MFGP) shares rose 3.1 percent to $18.40 in pre-market trading.

     

  • [By Money Morning Staff Reports]

    That’s why today we’ll show you one of our expert recommendations along with the 10 top-performing penny stocks to watch this week…

    Penny Stocks Current Share Price
    (as of Feb. 20) Feb. 12-20 Gain
    (as of Feb. 20)
    POET Technologies Inc. (OTCMKTS: POETF) $0.4165 85.1%
    Finjan Holdings Inc. (Nasdaq: FNJN) $2.94 67.05%
    Intelsat SA (NYSE: I) $3.50 38.89%
    Genesis Healthcare Inc. (NYSE: GEN) $1.39 37.62%
    Paringa Resources Ltd. (OTCMKTS: PNGZF) $0.41 32.30%
    CytoDyn Inc. (OTCMKTS: CYDY) $0.76 31.03%
    Iconix Brand Group Inc. (Nasdaq: ICON) $1.65 30.95%
    AMERI Holdings Inc. (Nasdaq: AMRH) $2.49 29.69%
    Pangea Logistics Solutions Ltd. (Nasdaq: PANL) $2.87 26.99%
    MoSys Inc. (Nasdaq: MOSY) $1.47 25.68%

    FREE PROFIT ALERTS: Get real-time recommendations on the best penny stock opportunities the moment we release them. Just sign up here, it’s completely free…

  • [By Lisa Levin] Gainers
    The Trade Desk, Inc. (NASDAQ: TTD) jumped 36.2 percent to $71.82 after the company reported upbeat results for its first quarter. The company also issued strong second-quarter and FY18 sales guidance.
    WideOpenWest, Inc. (NYSE: WOW) jumped 30.4 percent to $8.80 after the company reported Q1 results.
    MoSys, Inc. (NASDAQ: MOSY) shares surged 28.6 percent to $1.9541 after the company reported better-than-expected Q1 results and issued strong Q2 forecast.
    Boxlight Corporation (NASDAQ: BOXL) gained 24 percent to $6.39.
    Akcea Therapeutics, Inc. (NASDAQ: AKCA) shares gained 19.1 percent to $24.60. Akcea Therapeutics, an affiliate of Ionis Pharmaceuticals Inc (NASDAQ: IONS) announced that the Endocrinologic and Metabolic Drugs Advisory Committee, which met to discuss the safety and efficacy of subcutaneously injected volanesoren solution for patients with familial chylomicronemia syndrome, voted 12-8 to support its approval.
    Net 1 UEPS Technologies, Inc. (NASDAQ: UEPS) shares rose 17 percent to $10.31 after reporting Q3 results.
    ArcBest Corporation (NASDAQ: ARCB) gained 16.8 percent to $43.1457 after reporting upbeat quarterly earnings.
    Amtech Systems, Inc. (NASDAQ: ASYS) rose 16.2 percent to $8.60. Amtech posted Q2 earnings of $0.19 per share on sales of $32.783 million.
    Identiv, Inc (NASDAQ: INVE) surged 14.4 percent to $3.8450 following Q1 results.
    Omeros Corporation (NASDAQ: OMER) shares rose 14.3 percent to $18.43 following Q1 results.
    VivoPower International PLC (NASDAQ: VVPR) gained 11.5 percent to $2.71.
    Intersections Inc. (NASDAQ: INTX) gained 11.4 percent to $2.55 after reporting Q1 results.
    Noodles & Company (NASDAQ: NDLS) shares rose 10.9 percent to $8.65 following Q1 results.
    Voyager Therapeutics, Inc. (NASDAQ: VYGR) climbed 10.6 percent to $18.54 following Q1 results.
    Blink Charging Co. (NASDAQ: BLNK) rose 10.4 percent to $5.739.
    Immersion Corporation (NASDAQ: IMMR) gained 9.6 percent to $12.69
  • [By Lisa Levin]

    MoSys, Inc. (NASDAQ: MOSY) shares were also up, gaining 27 percent to $1.9265 after the company reported better-than-expected Q1 results and issued strong Q2 forecast.

  • [By Lisa Levin]

    MoSys, Inc. (NASDAQ: MOSY) shares were also up, gaining 21 percent to $1.84 after the company reported better-than-expected Q1 results and issued strong Q2 forecast.

Best Value Stocks To Invest In Right Now: Immunomedics, Inc.(IMMU)

Advisors’ Opinion:

  • [By Stephan Byrd]

    Celldex Therapeutics (NASDAQ: CLDX) and Immunomedics (NASDAQ:IMMU) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, institutional ownership and earnings.

  • [By Logan Wallace]

    Immunomedics, Inc. (NASDAQ:IMMU) Director Venbio Select Advisor Llc bought 575,000 shares of the company’s stock in a transaction on Friday, June 15th. The stock was bought at an average cost of $24.00 per share, for a total transaction of $13,800,000.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

  • [By Max Byerly]

    Swiss National Bank cut its holdings in Immunomedics, Inc. (NASDAQ:IMMU) by 4.1% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 203,050 shares of the biopharmaceutical company’s stock after selling 8,600 shares during the period. Swiss National Bank’s holdings in Immunomedics were worth $4,806,000 at the end of the most recent reporting period.

  • [By Max Byerly]

    Get a free copy of the Zacks research report on Immunomedics (IMMU)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Maxx Chatsko]

    Shares of Immunomedics (NASDAQ:IMMU) rose nearly 12% last month, according to data provided by S&P Global Market Intelligence. The $5 billion biopharma announced fiscal first-quarter and full-year 2018 financial results, although as a pre-commercial company, investors were more interested in the business updates provided. 

  • [By Todd Campbell]

    After unveiling positive results for its lead drug, sacituzumab govitecan, in breast cancer at the influential American Society of Clinical Oncology (ASCO) conference, shares in Immunomedics (NASDAQ:IMMU) rallied by as much as 14.7% today before settling in for a gain of 9.3% at 3 p.m. EDT.

Best Value Stocks To Invest In Right Now: United States Steel Corporation(X)

Advisors’ Opinion:

  • [By Joseph Griffin]

    Commerzbank Aktiengesellschaft FI trimmed its holdings in shares of U.S. Steel (NYSE:X) by 3.7% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 121,345 shares of the basic materials company’s stock after selling 4,606 shares during the period. Commerzbank Aktiengesellschaft FI’s holdings in U.S. Steel were worth $4,270,000 as of its most recent SEC filing.

  • [By Stephan Byrd]

    Shares of TMX Group Ltd (TSE:X) have been assigned a consensus rating of “Buy” from the six ratings firms that are currently covering the firm, MarketBeat reports. Two analysts have rated the stock with a hold rating and two have given a buy rating to the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is C$90.33.

  • [By ]

    United States Steel (X) : “We’ve got Nucor (NUE) and that’s the one you want to buy.”

    Del Taco Restaurants (TACO) : “We have so many others in that group, why go with this one?”

Best Value Stocks To Invest In Right Now: Wabash National Corporation(WNC)

Advisors’ Opinion:

  • [By Shane Hupp]

    Wabash National Co. (NYSE:WNC) shares reached a new 52-week low on Friday . The company traded as low as $17.91 and last traded at $18.09, with a volume of 33824 shares trading hands. The stock had previously closed at $18.51.

  • [By Tyler Crowe]

    It wasn’t that long ago that concerns about a downturn in the truck trailer business had investors concerned that Wabash National’s (NYSE:WNC) best days were behind it. Those concerns seem to have been overblown, though, as demand for Wabash’s products were high enough for management to raise its sales guidance for the year. 

  • [By Shane Hupp]

    Get a free copy of the Zacks research report on Wabash National (WNC)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Logan Wallace]

    Get a free copy of the Zacks research report on Wabash National (WNC)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Stephan Byrd]

    Get a free copy of the Zacks research report on Wabash National (WNC)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

Leave a Reply

Your email address will not be published. Required fields are marked *